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With the first publication of the cancer report in 1986, the cancer committee sought to provide
the 120 physicians on the medical staff of St. Cloud Hospital an overview of the local scope and
capabilities in diagnosis and treatment of cancer from 1976 through 1986. At this time, most
cancer treatment, including surgery and limited chemotherapy, was provided to inpatients, and
radiation oncology was vastly different. The cover for this report, pictured to the right, likely
interested only a few physicians as it pictured a microscopic cancer cell.
The first report included a focus study of breast cancer cases from 1976 to 1986 and highlighted
the availability of mammography in early detection of breast cancer. In 1976, a total of 33 new
breast cancers were diagnosed at St. Cloud Hospital. Only three (8.8%) of these breast cases
were discovered by mammography, and radical mastectomy was the preferred surgical
procedure for treatment.
The purpose of publishing an annual cancer report continues to be the provision of an overview of cancer
programming available in St. Cloud. The St. Cloud Hospital cancer registry annually tracks treatment and follow-up
data on more than 17,400 analytic cancer cases diagnosed between 1994 and 2008. Treatment information
is continually monitored to assure quality data capture thus allowing side-by-side comparison of screening,
diagnosis and treatment modalities provided locally to what’s available at any other accredited cancer program
in the United States.
Close partnerships between patients and their providers drive health care decisions today.
In addition, cancer care today requires a close communicative relationship with the
many highly skilled specialty and subspecialty physicians located in our community
and throughout Central Minnesota. Thus, the annual cancer report is intended to reach
a broad audience with more than 3,100 copies printed and is available on the CentraCare
Web site for access by literally anyone, anywhere.
Consumers use multiple resources to select a center for their cancer treatment. Their
decision is made by considering local physician expertise by cancer disease site,
availability of advanced treatments, cutting edge technology, local access to progressive
research and highly skilled, sensitive, compassionate staff. In addition, survivors seek
support programs that meet their long-term needs as they live a changed life post-cancer.
This annual report provides to the region an ongoing communication vehicle of our cancer programming and
capabilities. As an example, this year’s cancer focus studies — prostate, kidney and bladder— demonstrate
national benchmark findings and outcomes because of the close collaborative work and commitment of the
urology team at Adult and Pediatric Urology, St. Cloud Hospital and Coborn Cancer Center.
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The first publication
of the Cancer Report
in 1986
The 23rd annual publication
of the Cancer Report 2008
Cancer Report 2008 | 3
Achievements
Coborn Cancer Center is proud
to be a department of St. Cloud
Hospital and is equally proud
to provide the same high-quality
care that St. Cloud Hospital has
been so highly awarded for.
St. Cloud Hospital’s national
recognition includes:
• Magnet Award for Excellence
in Nursing (2004-2008,
2009-2013)
• Thomson Reuters Top 100
Hospital (1993, 1994, 1999,
2005-2008)
• An “America’s Best Hospital”
U.S. News &World Report
(2005-2008)
Breast Cancer Now — Quite a Change from 1976
• 412 physicians on active and associate medical staff at St. Cloud Hospital.
• 263 new breast cancers diagnosed in 2008.
• More than 60% of new cancers were found by mammogram which
generally results in the discovery of cancer at earlier stages leading to
better outcomes.
• The availability of sentinel node biopsy minimizes lymph node dissection.
• Only a minority of women require a modified radical mastectomy.
• Breast cancer diagnosis and treatment options are multifaceted including
screening with digital mammography, treatment with high dose radiation,
and use of biotherapy agents for cancer prevention. Also, a full range of
breast surgical options are available along with advanced reconstructive
capabilities. (Visit www.centracare.com for more details.)
What will never change
• Our commitment to providing our community with a cancer program
of the highest quality with technologically advanced capabilities,
centered around patient-focused care principles.
• Our dedication to partnerships with regional providers and academic
medical centers to ensure cutting edge capabilities at a local level.
• Our appreciation in being able to work with the many caring and
committed health care providers in Central Minnesota who daily
demonstrate their care and concern for those seeking their services.
All too often we don’t take the time to thank you for your commitment
to this cancer program.
• Our gratitude to the many patients, locally and nationwide
who have participated in clinical trials that have advanced
knowledge of effective cancer treatments.
• Our appreciation to the hundreds of employees in all our clinics
and hospitals who routinely go “above and beyond” to support
our patients and their families.
• Our gratitude to the Cancer Care Board members who annually donate
hundreds of hours to oversee and ensure that the broadest scope of
cancer services remain available locally.
Jo Zwilling, RN, MBA
Cancer Program Director
Nicholas F. Reuter, MD, FACP
Cancer Medical Director
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Roger Carlson,
prostate cancer survivor,
with his Harley Davidson
Electra Glide®
“It didn’t slow me down.”
Setting Higher Sights
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Upon the advice of his eye doctor and some prodding from family, Roger
Carlson, then age 53, went to his doctor to get a cholesterol test. “I felt fine,”
he said. “When I went in, my doctor saw I’d turned 50 and ordered
a PSA test for me.” That lucky series of events added up to
surprising results — prostate cancer.
Carlson chose daVinci technology offered at St. Cloud Hospital,
a minimally invasive technique with much quicker recovery and
fewer side effects, to treat his cancer. “I did a lot of research before
choosing the daVinci,” Carlson said.
After the surgery, Carlson had seven weeks of radiation and didn’t
skip a beat. “I was done with radiation a week before Labor Day
and that weekend took a 650 mile trip,” he said. “It didn’t slow me down.”
His cancer experience was a bump in the road, but with advanced technology
and comprehensive care, today Carlson is riding high.
John Mezera, 79, of St. Cloud has always loved aviation. He built model
planes, received his pilot’s license at age 18, served in the Air Force and had
a long career as a corporate pilot. Today, he is setting his sights even higher.
Not only does he and his co-pilot Teddy, his 5-year old Roosevelt Terrier,
devote time to youth by taking them flying to cultivate interest in aviation, but
after his diagnosis of prostate cancer in 1993, John enrolled in two research
studies. “I think it’s beneficial for everyone,” he said.
“I’ve had so many friends with prostate cancer. I would
definitely encourage others to participate in a clinical
trial.” By participating in research, Mezera is helping
to improve the care for others with prostate cancer.
Since 2008, the research departments of Adult & Pediatric
Urology and the Coborn Cancer Center have worked
together to assure the best clinical research trials are










St. Cloud Hospital Cancer Registry abstracted 237 new cases of prostate
cancer in 2008 compared to 177 cases in 1999. The number of cases in the
community is likely much higher as these numbers do not reflect men who
were diagnosed with prostate cancer and managed solely by Adult &
Pediatric Urology or their primary care physicians. Adult & Pediatric Urology
follows 3,510 men who have been diagnosed with the condition from 2004
through 2008 and are undergoing treatment or long term surveillance with
1,918 of these men seen during 2008. Over the past decade, the steady increase in
the number of prostate cancer diagnoses likely reflects increased patient awareness, a
dedication to provider education and aggressive screening with prostate-specific antigen
(PSA) blood test and digital rectal exam (DRE).
Screening
In 2009, the American Cancer Society (ACS) prostate cancer screening recommendations
were revised and now recommend a discussion between a physician and patient regarding
the potential risks and benefits of prostate cancer screening, as well as the options available
with early detection. The decision whether to screen is between physician and patient.
Stage at diagnosis
In 2008, the majority of prostate cancer patients
diagnosed and/or treated at St. Cloud Hospital were
stage II (Table 6). A review of comparison data from
the National Cancer Data Base (NCDB), shows 86%
of the cases diagnosed and/or treated at St. Cloud
Hospital were stage II. This compares favorably with
NCDB data from Minnesota hospital cancer registries
(82%) and national cancer registries (78%) (Table 1).
The early diagnosis rate likely reflects the efforts of
local primary care physicians who have been
aggressive in screening for early detection.
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The annual report last focused on
prostate cancer in 1999. Prostate
cancer continues to be the most
commonly diagnosed cancer in
our community and in the nation.
Since 1999, screening
recommendations have been
refined, public awareness has
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PROSTATE CANCER CASES BY AJCC STAGE
St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB)
2000 to 2006 Data
Source: NCDB, Commission on Cancer, ACoS. Benchmark Reports, v9.0, 2009
(AJCC) = American Joint Commission on Cancer
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Treatment
The treatment for prostate cancer depends upon the stage of disease,
aggressiveness of the tumor and age and medical condition of the patient.
Because most prostate cancers are diagnosed when the patient still has local
disease, there are many options available including active surveillance, surgery,
radiation, chemotherapy, hormone ablative therapy or a combination of these
treatments. Advances in surgical techniques within the past five years have
added more options for patients who choose surgery for treatment. New, less
invasive surgical techniques within the past five years include the da Vinci
Robotic laparoscopic prostatectomy, a less invasive approach that provides
an alternative to traditional open surgery; mini-laparotomy, a traditional
prostatectomy through a substantially smaller incision; and cryosurgery,
freezing of the prostate. For men with more advanced disease (stage IV),
the physicians at the cancer center now offer access to clinical trials offering
new chemotherapy/biotherapy agents designed to increase survival and
improve quality of life.
Survival
The five-year survival rate for all stages of prostate cancer at St. Cloud Hospital
is 89% compared to the national average of 85% (Table 2). Improvements
in survival rates may be attributable to earlier diagnosis as well as
improvements in treatment. Commitment of the local medical community




















Prostate Bladder Kidney/Renal Pelvis



















FIVE YEAR OBSERVED SURVIVAL RATES
PROSTATE, BLADDER AND KIDNEY/RENAL PELVIS
St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB)
1998 to 2001 Data
Source: NCDB, Commission on Cancer, ACoS. Benchmark Reports, v9.0, 2009
St. Cloud Hospital cancer program
has earned three-year accreditation
with commendation as a
Comprehensive Community
Cancer Program awarded by the
American College of Surgeons
Commission on Cancer. In
addition, at the time of the last
survey in 2007, the cancer
program was honored to receive
the “Outstanding Achievement”
award. This recognition of high
level achievement has been
earned by only about 15% of
cancer programs in the nation.
The purpose of the award is to:
• Recognize cancer programs
that strive for excellence in
providing quality care to
cancer patients;
• Motivate other programs to
work toward improving their
care; and
• Foster communication between
award recipients.
Kidney Cancer
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Incidence
The incidence of kidney cancer cases diagnosed and/or
treated at St. Cloud Hospital has increased 74% over
the past decade, with 38 patients seen in 1999 and
66 patients in 2008. As with prostate cases, kidney cases
are primarily managed by urology. Currently, Adult &
Pediatric Urology follows 423 patients who have been
diagnosed with kidney cancer from 2004 to present,
with 213 patients seen during 2008. National statistics
show that kidney and bladder cancer incidence is
significantly higher in men than women. This is
evidenced when comparing National Cancer Data Base
(NCDB) statistics and St. Cloud Hospital findings. (Table 3).
Stage at diagnosis
In 2008, the majority of kidney cases at St. Cloud Hospital were diagnosed while cancer was still confined to the
primary site, stage I or II (Table 6). Of St. Cloud Hospital cases diagnosed from 2000-2006, 60% were stage I to II,
comparing favorably to a rate of 62% from Minnesota hospital data and 56% from national data (Table 4). The
most common presenting complaints by patients with kidney cancer are 40% hematuria (blood in the urine),
40% flank pain and 25% palpable mass in the flank or abdomen. However, 25 to 30% of patients have no
complaints and their kidney cancer is found on incidental radiologic study.
Treatment
Unchanged from 1999, surgical removal of the kidney
cancer is still the primary treatment, with NCDB data
from 2006 showing that 79% of all St. Cloud Hospital
cases underwent surgery compared to 78% nationally.
Today, however, the number of surgical options has
increased to include both laparoscopic, open radical
and partial nephrectomy and kidney cryotherapy.
In addition, research activities have explored using
combinations of targeted drugs that block the growth
and spread of cancer by interfering with specific
molecules involved in tumor growth and progression.
Survival
St. Cloud Hospital’s five-year survival rate for all stages
of kidney cancer is 61%, comparing favorably to the
national rate of 56% (Table 2). There are no screening recommendations for kidney cancer. Quality outcomes
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KIDNEY/RENAL PELVIS CANCER CASES BY AJCC STAGE
St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB)
2000 to 2006 Data
Source: NCDB, Commission on Cancer, ACoS. Benchmark Reports, v9.0, 2009
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KIDNEY CANCER BLADDER CANCER
TABLE 3
KIDNEY AND BLADDER CANCER BY GENDER
St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB)
2000 to 2006 Data
Source: NCDB, Commission on Cancer, ACoS. Benchmark Reports, v9.0, 2009
Bladder Cancer
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Incidence
The number of bladder cancer cases reported annually by St. Cloud Hospital has increased from 42 cases in 1999
to 69 cases in 2008. As in kidney cancer, these numbers are not reflective of the total number of cases diagnosed
in our community as these patients are primarily managed by urology. The National Cancer Institute reports
the incidence of the disease in the United States has changed little over the past 20 years. Therefore, the
increase noted in St. Cloud likely reflects growth in Adult & Pediatric Urology and St. Cloud Hospital. Currently,
Adult & Pediatric Urology follows 819 patients, diagnosed from 2004 to present, with 373 patients seen in 2008.
For bladder cancer, men have a greater incidence (75%) than women (25%). This is supported by NCDB statistics
and St. Cloud Hospital findings (Table 3). The difference in gender incidence is not completely clear. Theories
include smoking rates, exposure to carcinogenic substances and variation differences in male hormone mechanisms.
Stage at diagnosis
In 2008, the majority of bladder cancer cases at St. Cloud
Hospital were diagnosed at an early (0 to I) stage. (Table 6).
This compares to NCDB data where 69% of St. Cloud
Hospital, 68% of Minnesota and 67% of national cases
were diagnosed in these early stages (Table 5).
Treatment
Treatment options depend on the stage of the cancer.
Patients diagnosed with superficial cancers may require
nothing more than a biopsy procedure. Patients with
recurrent tumors or superficial invasion may require
treatment with Bacillus Calmette-Guérin (BCG), a
medication placed in the bladder and urinated out.
Patients with invasive cancers may need the bladder
removed and an extended lymph node dissection. This
aggressive therapy is delivered through an incision in the low abdomen but in the near future may be available as a
robot-assisted laparoscopic procedure. Patients with metastatic cancer or high stage cancer may require chemotherapy
and possibly radiation therapy after bladder removal. Fortunately, most bladder cancers are found early allowing
bladder preserving treatments. Early detection depends on aggressive screening of patients with blood in their urine.
Survival
The 69% overall survival rates for bladder cancer at St. Cloud Hospital compares favorably with the 62% national
overall survival rate (Table 2). When comparing St. Cloud Hospital incidence, stage at diagnosis and survival rates
to NCDB rates there are no significant differences.
Summary
The providers of the St. Cloud community and St. Cloud Hospital are committed to improving patient survival by
aggressively screening patients at risk, offering cutting-edge treatment options and participating in research
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BLADDER CANCER CASES BY AJCC STAGE
St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB)
2000 to 2006 Data
Source: NCDB, Commission on Cancer, ACoS. Benchmark Reports, v9.0, 2009
(AJCC) = American Joint Commission on Cancer
Activity Report
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In 2008, there were 1,498 cases entered into the St. Cloud Hospital cancer registry. Although this was 115 cases
less than entered during 2007, the long term trend for new cancer diagnoses has continued to rise over the past
decade (Table 7). Our top five most frequently diagnosed cancers during 2008 were breast, prostate, colorectal,
lung and lymphoma. Coincidentally, the sixth and seventh most common sites are bladder and kidney/renal
pelvis, both included in
the focus report this year.
These top seven cancer
diagnoses account
for 72% of all 2008
St. Cloud Hospital cases.
The ratio of cases at this
facility compares well
with the estimated cases
for Minnesota and the
United States as published
in the American Cancer
Society’s “Cancer Facts
and Figures 2008”
(Table 8). The American
Cancer Society statistics
for breast do not include
stage 0 cases perhaps
explaining the higher
percentage of breast cases




Cancer standards are used
by the registry for data
collection procedures.
There are 17,472 analytic
cases in the registry for the
years 1994 to 2008. A
total of 9,433 patients are




AJCC STAGE GROUP* AT DIAGNOSIS: 2008 ANALYTIC CASES
(Total Cases and Top Seven Sites)
SITE 0 I II III IV UNKNOWN N/A** TOTAL
ALL CASES 141 352 391 192 225 23 174 1498
Breast 42 121 63 26 9 1 1 263
Prostate 0 0 208 19 10 0 0 237
Colorectal 50 37 27 34 27 5 2 182
Lung/Bronchus 0 29 20 43 82 6 2 182
Malignant Lymphoma 0 26 13 8 30 0 1 78
Bladder 38 11 10 2 7 1 0 69
Kidney/Renal Pelvis 3 38 4 11 9 1 0 66
* Collaborative Stage Derived
** N/A: (Not Applicable) refers to cancers that do not have an AJCC staging scheme
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ANALYTIC CASES BY YEAR




Submitted by Cancer Registry
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* Minnesota and nationwide statistics taken from the American Cancer Society (ACS) Facts/Figures 2008
** The ACS Facts and Figures do not provide 2008 Minnesota estimates for lymphoma or kidney cancer
INCIDENCE OF TOP CANCER SITES
(Compared to total number of cancers diagnosed)
SITE St. Cloud Hospital Minnesota* Nationwide*
Breast 18% 13% 13%
Prostate 16% 15% 13%
Lung/Bronchus 12% 14% 15%
Colon/Rectum 12% 10% 10%
Lymphoma 5% ** 5%
Bladder 5% 5% 5%
Kidney/Renal Pelvis 4% ** 4%
SITE INCIDENCE DATA AT ST. CLOUD HOSPITAL
ALL SITES 2006 2007 2008
Oral Cavity 26 47 24
Tongue 5 8 9
Oropharynx, Hypopharynx 2 2 00
Other 19 37 15
Digestive System 216 276 264
Esophagus 17 20 11
Stomach 12 22 22
Colon 107 126 137
Rectum, Rectosigmoid 33 50 45
Anus/Anal Canal 0 7 2
Liver & Bile Ducts 2 7 6
Pancreas 27 34 24
Other 18 10 17
Respiratory System 197 241 193
Larynx 11 9 8
Lung/Bronchus 180 226 182
Other 6 6 3
Hematopoietic/Lymphoid 150 141 153
Leukemia 31 35 29
Multiple Myeloma 21 15 18
Other Hematopoietic 27 21 28
Hodgkin Lymphoma 12 9 12
Non-Hodgkin Lymphoma 59 61 66
Bone 4 4 1
Connective/Soft Tissue 5 4 4
Skin 29 45 34
Melanoma 26 44 32
Other 3 1 2
Breast 256 273 263
Female Genital 51 43 51
Cervix Uteri 2 6 4
Corpus Uteri 34 20 30
Ovary 14 17 14
Other Female 1 0 3
Male Genital 265 302 248
Prostate 257 291 237
Testis 6 9 11
Other Male Genital 2 2 0
Urinary 150 138 138
Bladder 70 66 69
Kidney/Renal 75 69 66
Other Urinary 5 3 3
Brain and CNS 38 36 48
Brain (Benign) 1 1 1
Brain (Malignant) 20 19 25
Other Brain and CNS 17 16 22
Endocrine 51 40 46
Thyroid 41 35 40
Other Endocrine 10 5 6
Unknown Primary 22 20 24
Other/Ill-Defined 10 3 7
TOTAL 1470 1613 1498
TABLE 8
collected on more than 95% of these patients which
exceeds the Commission on Cancer’s requirement
of 90%. Cancer registry data is used internally for
quality outcome measures such as volume, survival
and use and adherence to clinical practice guidelines.
The data also is submitted to Minnesota’s state cancer
registry, the Minnesota Cancer Surveillance System,
which monitors the occurrence of cancer in Minnesota.
The registry also submits data to the Commission on
Cancer’s National Cancer Data Base (NCDB). The
NCDB contains data on more than 15 million cancer
cases from registries across the United States and
explores trends in cancer care, research and provides
benchmark data for participating institutions.
The registry continues to provide high-quality and
timely data for all cancers diagnosed and/or treated
at St. Cloud Hospital/
Coborn Cancer Center.
The work of Cancer Registry
is vital to our cancer care
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Donald Jurgens, MD,
is the Principal Investigator
at Coborn Cancer Center.
Harold Windschitl, MD, shown in 1978
when he was named medical chief of staff.
A glimpse back. . .
In 1977, Harold Windschitl, MD, of St. Cloud Hospital,
became one of seven pioneering physicians who aspired to
bring quality cancer care and research to Central Minnesota.
Pursuing this notion, they formed North Central Cancer
Treatment Group (NCCTG), a cancer clinical trials
cooperative group based at Mayo Clinic in Rochester, MN.
Under the leadership of Dr. Windschitl, St. Cloud Hospital accrued
the first cancer patient to a research study on February 4, 1978. During
the next six months, 13 patients were accrued to 12 studies. More
than 1,500 people were enrolled in clinical trials while Dr. Windschitl
acted as the Principal Investigator for research. Dr. Windschitl continued to lead the cancer research department
and be a contributing member of NCCTG for 30 years until his retirement in 2009.
Donald Jurgens, MD, took over the reins of the
Principal Investigator in late 2008. Dr. Jurgens graduated
from the University of Minnesota Medical School
and completed an internal medicine residency
and a hematology/oncology fellowship at Mayo
Graduate School of Medicine in Rochester, MN.
Continuing involvement with NCCTG, today the
research department has more than 60 cancer
research studies open and available, with access
to many more industry/pharmaceutical studies,
thus expanding the treatment options for our
patients and physicians. With assistance from the
Dr. Harold E. Windschitl Cancer Research Fund of
CentraCare Health Foundation, St. Cloud Hospital
and Coborn Cancer Center are committed to
supporting research in Central Minnesota.
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Cancer research facts:
• Nationally, 20% of cancer
patients are eligible to
participate in a clinical
trial.
• Nationally, 5% of cancer
patients participate in
clinical trials.
• $30 billion of pharmaceutical
money is spent on cancer
research each year.
• Approximately 8,000 clinical
trials are available through
the National Cancer
Institute.
• On average, it takes 8 years
for a cancer drug to receive
FDA approval.
• Today, we follow 240 people
on clinical trials at Coborn
Cancer Center.
• The Institutional Review
Board at St. Cloud Hospital
oversees clinical trial safety
for patients.
Patient advantages of participating
in a clinical trial:
• You may have more treatment options;
• You may be among the first to benefit from
a new drug or treatment;
• You may be helping future cancer patients; and
• Some medical care or tests may be paid by the
trial sponsor.
If you have questions or would like additional
information about cancer research trials, please visit
www.centracare.com or call (320) 229-4907.
Coborn Cancer Center would like to




































14 | Cancer Report 2008
Quality Cancer Care
We all want to believe that when people get cancer — including
ourselves and our relatives — they will get health care of the highest
quality. What is “quality” cancer care? How do we measure quality across the spectrum of cancer prevention,
diagnosis and treatment? There are national programs devoted to answering these questions and to identifying
the indicators of quality cancer care. Not an easy task. Cancer is complex.
The age of high speed technology has brought to the community practice setting, up-to-date, easily accessible
cancer guidelines for treatment. By monitoring use of these guidelines to assess process, how care is delivered
is a quality measure. Another frequently measured outcome is five-year survival rates. Some research has shown
correlation with the number of cases (volume) to be a positive factor in quality outcomes. However, quality
assessment also might evaluate structures (services and treatment
available, facility, providers), and other outcomes such as quality of life
and satisfaction with care.
While there is not yet one singular definition or measure for
quality cancer care, we are proactive in evaluating our
cancer care to assure the best is available to our
community and patients. The Coborn Cancer Center
also participates in numerous quality initiatives
through the Commission on Cancer (CoC),
the National Cancer Data Base (NCDB) and
the American College of Radiology (ACR).
The wisdom of using both internal and
external monitors to evaluate cancer
care provides an objective and
comprehensive look at our program.
Our cancer program has been
accredited by the CoC for 20 years.
The CoC is a consortium of professional
organizations dedicated to improving
survival and quality of life for cancer
patients through standard-setting,
prevention, research, education and
the monitoring of comprehensive quality
care. Accreditation by the CoC provides
access to national performance measures
and a means of providing data to the
NCDB. Through this process we are
provided with reports that compare our cancer program performance
to state and national benchmarks.
Debbie Linz, oncology scheduler, assists patients
at Coborn Cancer Center.
For additional information and a look
at our quality reporting measures for
breast, prostate and colorectal cancer,
please visit our Web site at
www.centracare.com, keyword
“cancer outcomes”.
60% of registered nurses at
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Coborn Cancer Center’s radiation oncology department
is one of three programs in the state of Minnesota to
be accredited by the prestigious American College
of Radiology (ACR). The ACR sets and assures quality
standards for radiation oncology and helps us
continuously improve the quality of care our patients
receive. The accreditation is voluntary and is designed
to be educational but also allows evaluation of personal
qualifications, equipment performance, effectiveness
of quality control measures, and quality of clinical
images. Ultimately, this accreditation monitors the
overall quality of patient care.
In high school, Richard Hirdler
was a gifted athlete. Today, at
age 69, he is still physically active, stating he can do 1,111 sit-ups
in 43 minutes with a 90-pound weight on his chest. So after a
PSA test and biopsy revealed prostate cancer, he fought it with
the same intensity he brings to the gym.
His doctor, Christopher Boelter, MD, a urologist at Adult &
Pediatric Urology, recommended a da Vinci Prostatectomy —
a minimally invasive, robotic-assisted surgical procedure that
removes the cancerous prostate gland and related structures.
Richard had his surgery October 3, 2008 and was discharged the
following afternoon – only 24 hours after the surgery. Compared
to previous hernia surgeries, Richard found that the da Vinci
Prostatectomy left him with smaller incisions, less scarring,
a shorter hospital stay and a faster recovery.
Richard now feels great and believes his prognosis is good. He still
works full time for the City of St. Cloud in the Street Department
and he continues to work out at the gym, deer hunt, fish and read.
Richard credits his quick recovery to a lifestyle that includes
exercise, the loving support of his wife and family and his faith.
Christopher Boelter, MD, Adult &
Pediatric Urology, frequently performs
prostatectomy procedures at St. Cloud
Hospital using the da Vinci surgical system.
Richard Hirdler, prostate
cancer survivor, continues
his active lifestyle at age 69.
Da Vinci surgical technology
is an example of how quality




The Cancer Survivorship Network enhances quality of life for patients and their families during and after treatment
by offering programs and services such as Art Therapy and Children’s Lives IncludeMoments of Bravery (CLIMB).
Art therapy is the process of expressing feelings
and emotions in a creative, non-verbal way.
It can help patients and loved ones relax and
heal, discover self awareness or cope with
pain and illness.
Katie Kinzer, master’s level art therapist, is
trained not only in the art medium but how
to help people and foster
healing. “Taking art therapy
classes more than once
or at different times in
your journey is definitely
beneficial,” said Kinzer.
“One project may tell you
about where you are at
a given moment but reviewing a series of
your art over a period of
time tells you more about
your journey.”
Art therapy projects may
include working with clay,
making a mask, watercolor
painting or drawing to
name a few.
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Survivorship
“Art allows me personal expression. It is
amazing what comes out from within and
what I learned about myself along the way.
It’s fun and freeing and helps me keep
my life and cancer journey in perspective
and balance.”
Mary, cancer survivor
Katie Kinzer, MA, leads the Art Therapy Program for patients and their family
members at Coborn Cancer Center.
In the United States, the American
Cancer Society estimates that more
than 315,000 parents with children
under 18 will be diagnosed with
invasive cancer each year. As
this number continues to rise,
Coborn Cancer Center recognizes
there are a number of children in
our region affected by cancer each
year. With financial support from
CentraCare Health Foundation, we
were able to launch our own
support program called CLIMB
(Children’s Lives Include Moments
of Bravery) — for children who
have a parent or grandparent
experiencing cancer.
In January 2009, we offered our first
session. This program offers six weekly,
90-minute group meetings, during which conversation and activities are used to help children (ages 6-11) identify
and appropriately express complex feelings. They are given their own notebook to capture their progress, which
they can share with their family at home.
Children bond very quickly with other children going through a similar experience. They learn that being sad,
frightened and even angry is part of the cancer experience. The sessions help children process feelings without
having to suppress them or feel overwhelmed by them.
e CLIMB Program will provide children with:
• A better understanding of cancer and its treatment;
• The ability to healthfully express their feelings and emotions;
• The ability to meet and share feelings with other children in similar situations,
and learn that “I’m not the only kid in school with a parent who has cancer”; and
• An understanding that cancer is “not their fault,” that they are not alone
and they are much better equipped to cope.
Programs such as Art Therapy and CLIMB are available thanks to the generosity of individuals in our community.
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®
CLIMB® Program
Lily (second from left) and Kaitlyn are shown with nurses Dawn Demant, RN,
(left) and Brenda Spoden, RN, who help lead CLIMB.
Drive-ru Colon Cancer Screening
saves lives
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Free colon cancer screenings were offered in March 2009, to nearly
500 individuals in Central Minnesota, thanks to the Hind-Site Alliance,
Minnesota Cancer Alliance and CentraCare Health System. The screenings
resulted in 32 positive findings for blood in participants’ stools.
Twenty participants consulted with their physicians. Fifteen received
additional workup, including 13 who underwent a colonoscopy —
the best method of detection for colon cancer. These
colonoscopies led to the diagnosis of adenomas
in three participants. Adenomas are a type of
polyp that, if left untreated, has the potential to
become cancerous. In addition to the above
cases, two patients were diagnosed with cancer.
Linda Hamre, of St. Cloud, was one of them.
Hamre was preoccupied with heart issues —
a quadruple bypass and a stint in her leg — but took advantage of a free drive through colon cancer screening.
“I had some concerns but was one of those people who never would have gotten a colonoscopy,” she said.
Hamre noticed an ad in the paper for free colon cancer screening kits
that could be done at home. “The kit was the step in between — just
what I needed,” she said. “I thought, why not? It’s free, private
and painless.”
This move may have saved 49-year old Hamre’s life. The screening
revealed blood in her stool. After a colonoscopy detected cancer, she
had surgery to have it removed and is back to her life as a wife,
grandmother and substitute teacher. “I am so grateful for the funds that
were donated to this program,” she said. “The screening kit that detected
my colon cancer early made the difference in my life. Who knows when
I would have gone in for a colonoscopy, it could have been too late for
me. I hope everyone will take advantage of this opportunity and also
have their colonoscopy done when it’s time.”
Colon cancer is the most preventable cancer as it has the highest number
of modifiable risk factors. Beginning at age 50, everyone should be screened every 10 years with a colonoscopy —
the “gold standard” for early detection. When colorectal cancer is found early and treated, the five-year relative
survival rate is 90%.
Stephanie & Doug Randolph
After Doug was diagnosed with colon cancer,
Doug & Stephanie set up the Hind-Site fund
through CentraCare Health Foundation to
support colon cancer education, screenings
and the promotion of complementary therapy.
Linda Hamre, colon cancer survivor, with her
granddaughter, Anastasia.
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Craig & Lynn Dahl Fund
Dr. Harold E. Windschitl
Cancer Research Fund
Cancer Named Funds
Fund-naming opportunities are available for the Coborn Cancer
Center. Our utmost gratitude from the staff, physicians and patients
who see your gifts impact cancer patients every day.
For more information on supporting these funds or creating
your own, please call the Foundation at (320) 240-2810.
For a list of individual benefactors, please visit
www.centracare.com/foundation/benefactors.html.
Generous Gis . . . Changing Lives
Community support
enhances the care we
provide. We express
our gratitude to those
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Family Medicine
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Otolaryngology
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Hematology/Oncology
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Director, Cancer Community Programs
Donald J. Jurgens, MD
Hematology/Oncology
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Medical Director, Radiation Oncology
Maria D. Mallory, MD
Surgery
Andre L. Mitchell, MD
Radiation Oncology
Paul J. Mitchell, MD
Surgery




Nathan P. Reuter, MD
Surgical Oncology
Nicholas Reuter, MD
Medical Director, Medical Oncology
Cathy Tieva, RN, OCN
Director, Inpatient Oncology
Jane Vortherms, RN, OCN
Director, Chemotherapy and
Oncology Clinic
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The 2007 Coborn Cancer Center annual report
was recognized by the Minnesota Health Strategy and
Communications Network. Entries were evaluated on
planning, approach, budget and results.
Innovative for care delivery,
Coborn Cancer Center brought
hospital and clinical cancer
services together in one location
in 2001. In 2007, the patient
experience was again enhanced
by the investment of a nearly
20,000-square-foot expansion.
Today, more people are living
with cancer. Our commitment
remains focused on “survivorship”
programs and resources to support
patients and their families through
their journey with cancer — from
the time they are diagnosed for
the rest of their lives.
Innovative care
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